CINECA IRIS Institutional Research Information System

GADDUCCI, ANGIOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.341
EU - Europa 20.775
AS - Asia 7.239
AF - Africa 186
SA - Sud America 93
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 11
Totale 60.669
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.933
IT - Italia 9.099
CN - Cina 3.625
SE - Svezia 2.859
BG - Bulgaria 1.975
UA - Ucraina 1.951
SG - Singapore 1.448
CA - Canada 1.396
DE - Germania 1.108
TR - Turchia 1.025
GB - Regno Unito 949
CH - Svizzera 887
FI - Finlandia 734
VN - Vietnam 668
RU - Federazione Russa 424
FR - Francia 321
HK - Hong Kong 256
IN - India 92
BE - Belgio 84
BR - Brasile 72
ES - Italia 55
CI - Costa d'Avorio 54
NL - Olanda 54
AT - Austria 46
NG - Nigeria 35
SN - Senegal 35
BJ - Benin 33
CZ - Repubblica Ceca 32
PL - Polonia 31
RO - Romania 26
IE - Irlanda 24
AU - Australia 19
PT - Portogallo 19
GR - Grecia 18
HU - Ungheria 18
EG - Egitto 12
IR - Iran 12
KR - Corea 12
EE - Estonia 11
ID - Indonesia 11
EU - Europa 10
JP - Giappone 10
DK - Danimarca 9
HR - Croazia 7
IL - Israele 7
LT - Lituania 7
MX - Messico 7
SA - Arabia Saudita 7
TW - Taiwan 7
MY - Malesia 6
PK - Pakistan 6
TH - Thailandia 6
ZA - Sudafrica 6
AL - Albania 5
AR - Argentina 5
CO - Colombia 5
IQ - Iraq 5
NZ - Nuova Zelanda 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
JO - Giordania 4
LK - Sri Lanka 4
LU - Lussemburgo 4
RS - Serbia 4
CY - Cipro 3
EC - Ecuador 3
NO - Norvegia 3
BD - Bangladesh 2
BN - Brunei Darussalam 2
CL - Cile 2
IS - Islanda 2
KE - Kenya 2
KG - Kirghizistan 2
MA - Marocco 2
MC - Monaco 2
MW - Malawi 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
TZ - Tanzania 2
UZ - Uzbekistan 2
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
DO - Repubblica Dominicana 1
GL - Groenlandia 1
IM - Isola di Man 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NP - Nepal 1
Totale 60.663
Salva come PNG Salva come JPEG
Città #
Milan 3.734
Chandler 3.224
Jacksonville 2.699
Woodbridge 2.680
Ann Arbor 2.524
Fairfield 2.246
Sofia 1.974
Houston 1.933
Ashburn 1.515
Ottawa 1.360
New York 1.128
Beijing 1.100
Santa Clara 1.003
Seattle 1.001
Wilmington 880
Singapore 849
Bern 845
Boardman 840
Princeton 800
Lawrence 774
Nanjing 769
Cambridge 683
Izmir 631
Des Moines 616
Medford 593
Dearborn 501
Jüchen 475
Rome 358
Istanbul 347
Dong Ket 330
Nanchang 265
Hong Kong 251
Redwood City 225
Kunming 198
San Diego 167
Boulder 154
Shenyang 132
Ogden 130
Hebei 108
Tianjin 108
Changsha 107
Hefei 102
Florence 100
Jiaxing 91
Verona 84
Brussels 82
Shanghai 82
Lancaster 80
Frankfurt am Main 78
Norwalk 77
Los Angeles 75
Orange 73
London 70
Serra 70
Chicago 59
Abidjan 54
Pune 54
Hangzhou 53
Pisa 53
Turin 48
Düsseldorf 47
Fuzhou 47
Guangzhou 47
Falls Church 42
Washington 42
Vienna 41
Changchun 40
Jinan 40
Dallas 39
Detroit 39
Bremen 37
Dakar 35
Cotonou 33
Grafing 32
Auburn Hills 30
Edinburgh 30
Bologna 29
Lagos 28
Torino 28
Palermo 26
Lanzhou 23
Quanzhou 21
Ningbo 20
Prague 18
Zhengzhou 18
Dublin 17
Helsinki 16
Naples 16
Phoenix 16
Pomezia 16
Walnut 16
Budapest 15
Genoa 15
Kent 15
Lissone 15
Madrid 15
Tappahannock 15
Ypsilanti 15
Zurich 15
Atlanta 14
Totale 42.705
Salva come PNG Salva come JPEG
Nome #
Chemioterapia con CTX,DDP,ADM nel carcinoma ovarico in stadio avanzato 1.586
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score 610
Isterectomia radicale secondo Wertheim-Meigs e radioterapia transcutanea postoperatoria con alte energie nel trattamento del carcinoma cervicale negli stadi Ib-II FIGO 345
Alfa2-macroglobulina e dismetabolismo glicidico in gravidanza 185
Chemioterapia neoadiuvante con schema PVB nel carcinoma cervicale avanzato. 185
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer 170
Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development. 164
A comparison of several tumor markers in the diagnosis, monitoring and follow-up of patients with epithelial ovarian cancer 162
Il recettore solubile dell' interleuchina-2(sIL-2r) nel carcinoma ovarico 162
Follow-up strategies in gynecological oncology: searching appropriateness 157
Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. 155
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer 151
Computed tomography in the follow-up of gynaecological neoplasias 147
Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic 147
Computerized tomography (CT) semeiotics in the presurgical evaluation of gynaecological neoplasias. 144
Carcinoma developing in bladder exstrophy. Case report. 143
Il dosaggio sierico del recettore solubile della interleuchina-2 nelle neoplasie ginecologiche 143
Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: Is local therapy with hyaluronic acid of clinical benefit? 143
Prospective multicenter study on CA 125 in postmenopausal pelvic masses. 141
First-line chemothe¬rapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients 141
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue 141
Combined use of CA125 and CA15-3 in patients with endometrial carcinoma. 140
Micro-RNAs and ovarian cancer: The state of art and perspectives of clinical research 140
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest 138
Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature 138
Valutazione del CA125, TPA, GICA, CEA nella diagnosi e nel monitoraggio del carcinoma ovarico. 137
D-dimer in gynecological cancer 137
The role of the French-Italian glossary of complications in the outcome evaluation of cervical cancer treatment: an Italian multicentric study 136
Wertheim's radical hysterectomy with pelvic lymphadenectomy in the treatment of cervical carcinoma at the Obstetric and Gynecological Clinic of the University of Pisa 135
Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study) 134
La tomografia assiale computerizzata nel follow-up delle pazienti precedentemente trattate per neoplasie della cervice e del corpo uterino 133
An analysis of approaches to the management of endome¬trial cancer in North America: A CTF study. 133
Current management of fallopian tube carcinoma 133
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. 133
Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature 132
Prognostic role of immunosuppres¬sive acidic protein in advanced ovarian cancer. 130
Carcinosarcoma of the uterus : a clinicopathological multicenter CTF study 130
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 130
Prognostic value of lymph node status and number of removed nodes in patients with squamous cell carcinoma of the vulva treated with modified radical vulvectomy and inguinal-femoral lymphadenectomy. 129
Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma 129
A comparison of the usefullness of serum measurements of CA125, CA50 and TATI in patients with malignant and benign gynecological pathology 129
Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research 129
Metabolismo glicidico ed emoglobina glicosilata (HbA1) in gravidanza 128
Adjuvant treatment of early stage ovarian carcinoma. 128
Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. 128
Prognostic factors in uterine sarcoma 128
Fertility drug use and risk of ovarian tumors: a debated clinical challenge 128
The therapy of verrucous carcinoma of the vulva. Observations on three cases. 127
Porphyrin-sensitized phototreatment as a conservative therapy in gynaecological oncology 127
Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study 127
Management of borderline ovarian tumors: Results of an Italian multicenter study 127
Weekly epirubicin in the treatment of gestational breast cancer (GBC) 127
Discontinuation of modern hormonal contraceptives: an Italian survey 127
Brenner's tumor 126
Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study 126
Preoperative evaluation of D-Dimer and CA 125 levels in differentiating benign from malignant ovarian masses. 126
The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis 125
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS) 125
Minimization of cisplatin nephrotoxicity in high-risk patients 124
Uterine leiomyosarcoma: Analysis of treatment failures and survival 124
The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients 123
p53 nuclear accumulation in adenomatous hyperplasia and stage I endometrioid carcinoma. 123
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study 123
Evaluation of the central dopaminergic activity in gestational hyperprolactinaemia by means of the electroretinographic technique 122
Evaluation of FHIT gene alterations in ovarian cancer 122
Aspetti colposcopici, citologici, e istologici dell'endometriosi cervicale. 121
Prothrombin fragment F 1+ 2 and thrombin- antithrombin III complex (TAT) plasma levels in patients with gynecological cancer 121
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer 121
Surveillance of patients after initial treatment of ovarian cancer 121
Epidoxorubicin (EPI-DX) and lonidamine (LND) in refractory or recurrent epithelial ovarian cancer (EOC) 120
Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study 120
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients 120
Adjuvant treatment and analysis of failures in patients with high-risk FIGO Stage Ib-II endometrial cancer: An Italian multicenter retrospective study (CTF study) 120
Fattori prognostici nei tumori misti mulleriani maligni (MMMT) dell' utero al I-II stadio: uno studio CTF 119
Endometrial stromal sarco¬ma: Analysis of treatment failures and survival 119
Struma ovarii 118
Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer 118
Iperprolattinemia e stati depressivi 117
Factor VIIIR: Ag plasma levels in patients with cervical and ovarian carcinoma 117
Surgery and radiotherapy in the treatment of early stage uterine sarcomas. 117
Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer. 117
Pharmacological treatment for uterine leiomyosarcomas 117
Intraperitoneal carboplatin with or without interferon-a in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients 116
The evolving role of adjuvant therapy in endometrial cancer 116
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 115
P53 overexpression in ovarian cancer: correlation with clinicopathological parameters and chemosensitivity 114
Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic 114
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1 114
Assenza di alterazioni dell'oncogene MDM-2 nel carcinoma ovarico 113
Survival after intestinal obstruction in patients with fatal ovarian cancer: Analysis of prognostic variables 113
Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study 113
Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study 113
The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. 113
Serum solule interleukin-receptor (sIL-2R) assay in cervical an endometrial cancer. Preliminary data. 112
Breast cancer in pregnancy: a real clinical challenge 112
Pregnancy-associated cancers: Frequency and temporal trends in Italy 112
The role of computerized tomography of the pelvis in the presurgical staging of carcinoma of the cervix and of the ovary Eur.J. Gynaec. 111
Le complicanze postoperatorie dell'intervento di laparoisterectomia radicale con linfadenectomia pelvica 111
A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma. 111
Is there a role for postoperative treatment in patients with stage Ib 2-IIb cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study 111
Totale 15.075
Salva come PNG Salva come JPEG
Categoria #
all - tutte 165.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 165.443
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.454 0 0 0 0 0 790 883 419 889 444 890 139
2020/20215.749 645 128 577 201 685 265 826 449 384 458 277 854
2021/20227.668 194 545 307 678 1.516 1.000 189 360 281 148 344 2.106
2022/20238.048 1.124 683 424 699 1.172 1.282 115 727 1.124 58 531 109
2023/202410.127 1.958 1.282 1.654 828 1.404 1.301 266 302 169 121 135 707
2024/20254.288 149 1.021 226 1.116 958 818 0 0 0 0 0 0
Totale 61.220